Development, optimization, and in vitro evaluation of atorvastatin calcium and vinpocetine codelivery by solid lipid nanoparticles for cancer therapy

Lala, Rita R.; Shinde, Amol S.

doi:10.1186/s43094-021-00351-y

Future Journal of Pharmaceutical Sciences

Table 4 Optimized coded batches and results of coded batches

From: Development, optimization, and in vitro evaluation of atorvastatin calcium and vinpocetine codelivery by solid lipid nanoparticles for cancer therapy

Coded batches	A D:L (mg)	B Surfactant: co-surfactant (mg)	C Homogenization speed (RPM)	Y1 Particle size (nm)	Y2 % EE (ATS)	Y3% EE (VIN)	Y4 % DL	PDI	ZP (-emv)
F1	100: (450:450)	500:500	7000	398 ± 4.2	55 ± 2.21	57.5 ± 1.54	5.55 ± 0.35	0.593 ± 0.0.8	32.7 ± 0.65
F2	100: (575:575)	333:667	9000	446 ± 2.8	60 ± 0.83	62.05 ± 2.24	4.75 ± 0.8	0.417 ± 0.06	− 29.2 ± .0.91
F3	100: (450:450)	120:880	7000	323 ± 6.0	64.69 ± 1.1	65.98 ± 0.91	6.49 ± 0.76	0.333 ± 0.02	− 30.4 ± 0.66
F4	100: (450:450)	1000:0	7000	479 ± 2.5	44.93 ± 1.56	50.67 ± 1.84	4.6 ± 0.58	0.648 ± 0.10	− 32.6 ± 0.15
F5	100: (325:325)	1000:0	9000	457 ± 7.1	45.4 ± 2.73	38.3 ± 3.9	6.02 ± 0.45	0.69 ± 0.12	− 38.2 ± 0.19
F6	100: (660:660)	500:500	7000	591 ± 5.3	52.74 ± 3.26	50.3 ± 2.81	4.11 ± 0.86	0.454 ± 0.06	− 56.2 ± 1.5
F7	100: (325:325)	1000:0	5000	429 ± 3.0	55.67 ± 2.32	57.76 ± 1.96	7.62 ± 0.91	0.403 ± 0.05	− 35.3 ± 0.7
F8	100: (480:480)	500:500	7000	409 ± 4.3	56 ± 0.94	53.9 ± 1.35	7.61 ± 0.23	0.612 ± 0.09	-25.2 ± 0.98
F9	100: (575:575)	1000:0	5000	615 ± 5.6	58.46 ± 1.32	53.6 ± 2.45	4.52 ± 0.11	0.62 ± 0.07	− 34.3 ± 0.58
F10	100: (325:325)	333:667	9000	426 ± 8.4	54.74 ± 1.58	49.83 ± 2.17	7.36 ± 0.14	0.574 ± 0.08	− .35.1 ± 1.5
F11	100: (325:325)	333:667	5000	436 ± 1.9	56.73 ± 0.74	42.8 ± 0.35	7.3 ± 0.097	0.334 ± 0.05	17.9 ± 1.4
F12	100: (450:450)	500:500	3636.41	532 ± 9.5	47.7 ± 1.44	42.65 ± 0.79	4.67 ± 0.1	0.867 ± 0.15	− 30.7 ± 2.23
F13	100: (450:450)	500:500	10,363.6	518 ± 5.6	47 ± 0.89	40.6 ± 2.1	4.57 ± 0.192	0.513 ± 0.06	− 32.7 ± 1.85
F14	100: (575:575)	1000:0	9000	537 ± 4.5	52.73 ± 2.32	41.45 ± 3.04	3.97 ± 0.108	0.735 ± 0.11	− 36.9 ± 1.52
F15	100: (575:575)	333:667	5000	465 ± 4.0	58.62 ± 1.84	54.07 ± 1.12	4.53 ± 0.16	0.396 ± 0.04	− 34.4 ± 1.62

Optimized coded batches: F1–F15, amount of poloxamer (used as a stabilizer)-200 mg, ratio of lipid- mixture used (GMS: Precirol ATO 5)—1:1, total amount of surfactant and co-surfactant mixture (Tween 80 and Labrasol)—1000 mg

Back to article page